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Pagnetically Targeted Endothelial
ell Localization in Stented Vessels
orin V. Pislaru, MD, PHD,* Adriana Harbuzariu, MD,* Rajiv Gulati, MD, PHD,* Tyra Witt,*
icole P. Sandhu, MD, PHD,† Robert D. Simari, MD, FACC,* Gurpreet S. Sandhu, MD, PHD, FACC*
ochester, Minnesota
OBJECTIVES A novel method to magnetically localize endothelial cells at the site of a stented vessel wall
was developed. The application of this strategy in a large animal model is described.
BACKGROUND Local delivery of blood-derived endothelial cells has been shown to facilitate vascular healing
in animal models. Therapeutic utilization has been limited by an inability to retain cells in the
presence of blood flow. We hypothesized that a magnetized stent would facilitate local
retention of superparamagnetically labeled cells.
METHODS Cultured porcine endothelial cells were labeled with endocytosed superparamagnetic iron
oxide microspheres. A 500:1 microsphere-to-cell ratio was selected for in vivo experiments
based on bromo-deoxyuridine incorporation and terminal deoxynucleotidyl transferase
mediated dUTP nick end labeling assays. Stents were magnetized and implanted in porcine
coronary and femoral arteries using standard interventional equipment. Labeled endothelial
cells were delivered locally during transient occlusion of blood flow.
RESULTS The delivered cells were found attached to the stent struts and were also distributed within
the adjacent denuded vessel wall at 24 h.
CONCLUSIONS Magnetic forces can be used to rapidly place endothelial cells at the site of a magnetized
intravascular stent. The delivered cells are retained in the presence of blood flow and also
spread to the adjacent injured vessel wall. Potential applications include delivering a cell-based
therapeutic effect to the local vessel wall as well as downstream tissue. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.0692006;48:1839–45) © 2006 by the American College of Cardiology Foundation
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the complete endothelialization of implanted cardiovascu-
ar devices such as stents, vascular grafts, and valves may
ake several months (1,2). Although drug-eluting stents
ave substantially reduced the incidence of restenosis (3),
ecent reports now describe late stent thrombosis (4–6) and
n increase in late neointima formation (7). Sirolimus, while
xerting beneficial anti–smooth-muscle cell effect, may also
mpair re-endothelialization via direct effect on circulating
rogenitor cells (8). The requirement for prolonged dual
nti-platelet therapy leads to an increased risk for bleeding-
elated complications (9), and any premature discontinua-
ion leaves individuals at risk for stent thrombosis, with
onsequent high morbidity and mortality (6). Previous
ethods of placing endothelial cells on intravascular stents
ave included precoating stents with cultured cells (10–13)
nd capturing cells with ligands or antibodies attached to
he stents (14). The recruitment strategies are limited by the
mall number of progenitor cells in circulation and may
esult in non-specific capture of inflammatory cells.
Local delivery of cultured cells has also been described but
s limited by the requirement for prolonged occlusion of
lood flow. Among other intravascular devices, synthetic
ascular grafts coated with autologous endothelial cells
emonstrated improved patency rates in a report published
n 1978 (15). Development of earlier strategies was hampered
y an inability to generate an adequate number of endothelial
From the *Division of Cardiovascular Diseases and †Division of General Internal
edicine, Mayo Clinic College of Medicine, Rochester, Minnesota. This research
as supported by the National Institutes of Health (HL75566 to Dr. Simari).i
Manuscript received May 3, 2006; revised manuscript received June 26, 2006,
ccepted June 26, 2006.ells from autologous sources. Endothelial cells can now be
ultured from circulating progenitors, and these cells appear to
e capable of facilitating re-endothelialization and can normal-
ze vascular function in injured vessels (16–21). We have
reviously shown (22) that magnetic forces can be used to
apture and retain superparamagnetically labeled endothe-
ial cells on modified vascular grafts. This report describes
he results of superparamagnetic cell labeling and the rapid
ttachment of these labeled cells to magnetized stents placed
n porcine coronary and femoral vessels. This novel method
f magnetic cell targeting may have multiple future clinical
pplications, including the ability to provide localized or
egional cell-based therapies.
ATERIALS AND METHODS
eneration of endothelial outgrowth cells. Peripheral
lood mononuclear cells were isolated from 50 to 200 ml
orcine blood by Ficoll density gradient (Histopaque 1077,
mersham, Piscataway, New Jersey) as previously described
17). These were placed on fibronectin-coated plates and
rown in endothelial basal culture media (EBM) supple-
ented with EGM-2 SingleQuotes (Cambrex, Baltimore,
aryland). The presence of highly proliferative cells with
ndothelial characteristics (endothelial outgrowth cells
EOCs]) was noted after 7 to 10 days. Our laboratory
17–19) and others (16,23) have previously described the
unctional and phenotypic characteristics of these cells. A
otal of 2 weeks in culture yielded large numbers of cells for
n vitro and in vivo experiments.
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Magnetically Targeted Cell Localization November 7, 2006:1839–45ell labeling. Superparamagnetic microspheres (SPM)
0.9 micrometer diameter, 63.4% iron oxide, pre-coated
ith a green fluorescent tag; Bangs Labs, Fishers, Indiana)
ere added to the EGM-2 culture media at serial concen-
rations for the in vitro studies. For in vivo experiments, a
00 SPM particles/cell co-incubation ratio was selected
ased upon the in vitro results as described later. Cells were
o-incubated with SPM at 37°C for 16 h, washed 3 times in
hosphate-buffered saline, trypsinized, and used in subse-
uent experiments. Endothelial outgrowth cells were la-
eled with a second fluorescent tag by incubation with the
ed carbocyanine tag CM-DiI (Molecular Probes Inc.,
ugene, Oregon) at 37°C for 30 min.
ffects of iron loading on cell survival, proliferation, and
unction. Endothelial outgrowth cells were incubated with
scalating doses of SPM particles (SPM-to-EOC ratio of 0
o 4,000/cell). Cell proliferation was assessed by spectro-
hotometric measurements of the bromo-deoxyuridine
BrdU) incorporation in replicating cellular deoxyribonu-
leic acid (Cell Proliferation ELISA, BrdU colorimetric,
oche, Nutley, New Jersey). The superparamagnetic parti-
les within cells were associated with substantial back-
rounds; therefore, cell-free supernatants were analyzed in
6-well plates using a standard plate reader (Spectra Max
lus Plate Reader, Molecular Devices, Sunnyvale, Califor-
ia). Endothelial outgrowth cell apoptosis after exposure to
PM was evaluated with the terminal deoxynucleotidyl
ransferase mediated dUTP nick end labeling (TUNEL)
ethod (In Situ Cell Death Detection Kit, TMR red,
oche). All experiments were performed at least in
riplicate.
To characterize the effects of SPM loading on EOC
unction, we plated EOCs on 6-well plates coated with
uman fibronectin and added SPM at a 500:1 ratio. Control
OCs were plated without SPM. To avoid contamination
rom EGM-2 SingleQuotes, EBM alone was used in these
xperiments. The conditioned medium was concentrated
ith a CentriCon tube and analyzed on the Human
ytokine Array V (RayBiotech, Norcross, Georgia). This
etection system is designed for qualitative analysis of
roteins present in conditioned media. Proteins specifically
ound to spots of a membrane and were detected by a
ocktail of biotin-conjugated antibodies (for 72 different
ytokines). After incubation of the membrane with horse-
adish peroxidase–conjugated streptavidin and detection
olution, the membrane was exposed to Biomax MR film
Abbreviations and Acronyms
BrdU  bromo-deoxyuridine
EOC  endothelial outgrowth cell
MRI  magnetic resonance imaging
SPM  superparamagnetic microsphere
TUNEL  terminal deoxynucleotidyl transferase
mediated dUTP nick end labelingKodak, Rochester, New York). wevelopment of magnetizable stents. A variety of stain-
ess steel, chromium cobalt, and nitinol stents were exposed
o a 5,000 G magnetic field generated by a neodymium-
ron-boron supermagnet. These commercially available
tents did not retain any significant magnetic charge capable
f attracting SPM-loaded cells. Multiple grades of steel;
ickel; and alloys such as Monel, Permalloy, Nitinol, and
ickel chromium were obtained in a 0.005- to 0.010-inch
iameter wire form (McMaster Inc., Atlanta, Georgia) so as to
pproximate the dimensions of stent struts. We magnetized
0-mm wire loops by a 5-min exposure to the neodymium
upermagnet. An electromagnetic degaussing device was
sed to demagnetize the negative control wires. The ability
o attract labeled cells was evaluated by live video recording.
agnetized nickel provided excellent cell capture but does
ot have the structural properties required for stent con-
truction. We therefore combined the structural properties
f steel with the magnetic properties of nickel by coating
ommercially available stainless-steel stents with a 10-m-
hick layer of nickel. Ferrofluid (10-nm magnetite particles
ispersed in liquid base) was brought into contact with the
tent to define the magnetic field generated by the magne-
ized struts. The magnetite particles in ferrofluid align with
agnetic fields and can be visualized with light microscopy.
his mapping demonstrated the presence of uniformly
istributed small magnetic domains on the surface of the
truts. Confocal and scanning electron microscopy showed
n evenly distributed adherence of SPM-loaded EOCs on
hese plated stents. The ability to attract and retain iron-
oaded cells in flow conditions was tested by exposing
agnetized stents to a circulating suspension of iron-loaded
OCs at various flow rates. The stents were then inspected
y standard fluorescent and confocal microscopy.
orcine studies. All animal experiments were performed
n accordance with the “Position of the American Heart
ssociation on Research Animal Use” and were approved by
he Institutional Animal Care and Utilization Committee of
he Mayo Clinic. Domestic pigs weighing 30 to 40 kg were
sed. We obtained 200 ml blood under sedation 2 weeks
efore intervention and used it for generation of autologous
OCs. Superparamagnetic microsphere loading was per-
ormed by a 16-h co-incubation with EOCs at a 500:1
PM-to-EOC ratio. The cells were then labeled with
M-DiI on the morning of the experiment. The animals
ere sedated with a combination of ketamine and xylazine
nd anesthetized with isoflurane. The carotid arteries were
issected free and 9-F arterial sheaths were placed under
terile conditions. Arterial segments devoid of visible side
ranches in the superficial femoral and coronary arteries
ere selected for delivery. Denudation of the targeted
egment was performed by passing back and forth an
versized balloon (balloon-to-vessel ratio of 1.2 to 1.4) for a
otal of 5 times. Nickel-coated stainless steel stents were
rought into contact with the 5,000 G neodymium magnet
or 5 min and were deployed in the vessel with an over-the-
ire balloon catheter. Control non-magnetized stainless
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November 7, 2006:1839–45 Magnetically Targeted Cell Localizationteel stents were placed either immediately upstream or
ownstream of the nickel-coated stent. The balloon was
hen withdrawn until the tip was just proximal to the
eployed stents and was re-inflated at low pressure. Com-
lete vessel occlusion was confirmed by injecting a small
mount of contrast material upstream from the balloon. The
uidewire was withdrawn, and the central lumen of the
alloon was used for cell delivery. Approximately 2.5 to 6 
06 autologous EOCs suspended in 4 ml PBS were injected
ver 2 min and blood flow was restored after a total
cclusion time of 5 min in the coronary arteries. The
emoral artery underwent a longer total occlusion time of 10
in. The adjacent magnetized and control stent deploy-
ent enabled us to expose both stents to similar cell loads
nd flow conditions in a single artery. All animals received
ral aspirin (325 mg/day) and clopidogrel (75 mg/day) for 5
ays before the procedure and on the day after procedure
ay. The animals were allowed to recover and were sacri-
ced 24 h after stent deployment. The targeted femoral and
oronary artery segments were carefully dissected and im-
ersed in cold phosphate-buffered saline. The vessels were
hen sectioned longitudinally into 2 halves and the stent
truts carefully removed. The arterial segments and corre-
ponding stent struts were examined by en face confocal or
uorescent microscopy. The presence of dual-labeled cells
green from the superparamagnetic iron microspheres and
ed from CM-DiI) was evaluated by visual inspection, and
mages were captured at low (40) and high (200)
agnifications. The number of labeled cells was then
ounted on 10 random high-power fields selected from
egments corresponding to the coated and control stents.
tatistical analysis. Statistical analysis was performed us-
ng SAS software (SAS, Cary, North Carolina). The normal
istribution was tested with the Shapiro-Wilk statistic, and
ransformations were performed when appropriate. Data
ere analyzed with one- or two-way ANOVA as appropri-
igure 1. Escalating superparamagnetic microsphere dose inhibits cell
roliferation. Exposure of endothelial outgrowth cell (EOC) to escalating
oses of superparamagnetic microsphere (SPM) results in a small but
ignificant decrease in bromo-deoxyuridine (BrdU) incorporation at high,
ut not at low doses. * p  0.05 versus no SPM.te. Tukey’s t test was used for multiple pairwise compari-
t
aons. Pearson’s correlation coefficient was used for evaluat-
ng the relationship between cell dose and corresponding
tent counts. A p value of 0.05 was considered significant.
ata are presented as mean values  SD.
ESULTS
n vitro experiments. The effects of SPM particle loading
n BrdU incorporation are given in Figure 1. There was a
inimal decrease in proliferation at a 500:1 SPM to EOC
o-incubation dose. However, a statistically significant re-
uction in proliferation was noted at higher doses. Similar
esults were observed during TUNEL staining. A minimal
ncrease in apoptosis was noted up to 500:1 SPM-to-EOC
o-incubation ratio, with significant cell death occurring at
igher doses (representative images shown in Figs. 2A and
B). Cytokine array studies (Figs. 2C and 2D) also dem-
nstrated no change in the secretory profile of EOCs after
PM loading at the 500:1 ratio. On the basis of these
esults, and on our observation that cells could easily be
ttracted to magnetized metallic devices at a 500:1 SPM-
o-EOC ratio, we selected this dose for subsequent in vivo
xperiments.
The ability of magnetized metallic devices to attract
PM-loaded EOCs is illustrated in Figure 3. Confocal
icroscopy showed the presence of large numbers of dual-
igure 2. Apoptosis and secretory profiles are stable with low-dose SPM. (A
nd B) Terminal deoxynucleotidyl transferase mediated dUTP nick end
abeling (TUNEL) assays: composite confocal images. Green fluorescence is
iven by SPM whereas red fluorescence represents TUNEL-positive apoptotic
ells. Exposure to SPM at a 500:1 ratio results in minimal apoptosis (A),
hereas significantly increased presence of apoptotic cells is evident at a higher
PM to EOC ratio (B, 4,000:1 ratio). (C and D) Cytokine array studies.
OC secretory profile was very similar for untreated cells (C) and cells exposed
o SPM at a 500:1 ratio (D). The top four left dots and bottom two right
ots are built-in positive controls of the array. All other dots represent an
ndividual cytokine (72 in total). With these studies, secretion of interleukins
IL)-8 and IL-10; growth factors EGF, HGF, and GDNF; and metallopro-
einase inhibitors TIMP-1 and TIMP-2 and MIP-1b were identified. Other
bbreviations as in Figure 1.
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Magnetically Targeted Cell Localization November 7, 2006:1839–45abeled cells on the magnetized but not on the control
evices with degaussed stainless steel wire loops (Figs. 3A
nd 3B). Nickel coating of commercially available stainless-
teel stents resulted in improvement of magnetic properties.
errofluid mapping demonstrated the presence of small
agnetic domains along the stent struts (Fig. 3C). These
mall magnetic domains resulted in a more uniform cover-
ge of cells on the stent struts, as shown in the confocal
icroscopy image (Fig. 3D). These magnetic forces were
trong enough to allow retention of cells on the stent struts
n flow conditions as high as 200 ml/min. An increase in
ow rates above this level resulted in progressive cell loss
data not shown). Transmission electronic microscopy (Fig.
E) shows the endocytosed SPM particles within the
ytoplasm of the EOCs. Scanning electronic microscopy at
he time of capture shows spherical cells on the stent surface
Fig. 3F).
n vivo experiments. A total of 10 animals were used in
his study, and a total of 24 stents were implanted: 11 in the
oronary arteries (7 magnetized, 4 non-magnetized control
nimals) and 13 in femoral arteries (10 magnetized, 3
on-magnetized control animals). An average of 3.7 
.3  106 cells was delivered per artery (range 2.5 to 6 
06 cells/artery).
All stented arteries were widely patent 24 h after implan-
ation. The delivery of SPM-loaded cells resulted in a
ignificant retention of cells at the site of the magnetized
tent (220  156 cells/high-power field). Very few cells
ere seen in the region with non-magnetic stents and no
ells were seen in areas immediately proximal or distal to the
eployment site. The presence of the magnetized stent was
ssociated with a statistically significant 6- to 30-fold
ncrease in the number of retained cells in both the coronary
nd femoral positions (p  0.01). Representative en face
icroscopic images are given in Figures 3G and 3H.
lightly better EOC retention was noted in the coronary
essels for both magnetized and control stents (Fig. 4A).
here was no significant correlation between the EOC dose
nd the number of cells retained at the site of either
agnetic or non-magnetic stents (r2  0.003 and r2 
.023 respectively; p  NS for both). Low-power images
emonstrated localization of cells in the vessel wall along
he stent struts as well as within the adjacent denuded areas
Fig. 4B).
ISCUSSION
he deployment of intravascular stents results in endothelial
enudation over approximately 40% of the stented surface
24). Under normal conditions, endothelial cells gradually
epopulate the denuded areas and cover the surface of
mplanted cardiovascular devices such as stents, valves, and
ascular grafts over a period of weeks to months. The ability
o rapidly “endothelialize” implanted devices could acceler-
te local healing and thereby reduce the risk of thrombosis.igure 3. SPM-labeled EOCs: interactions with magnetic fields. (A and
) Stacked confocal images obtained along the z-axis (100 magnifica-
ion). EOCs are labeled with CM-DiI (red) and SPM (green). Exposure
f SPM-loaded EOCs to a degaussed stainless steel loop does not result in
ignificant cell attraction (A). On the contrary, in the presence of a
agnetized stainless steel loop, SPM-loaded cells are rapidly cleared from
he suspension and accumulate predominantly on the loop bend (B). A
reen reflection from the stainless-steel loop is evident. (C and D) Nickel
oating of a commercially available stent results in multiple, small,
niformly distributed magnetic domains, as shown in ferrofluid studies (C).
resence of numerous magnetic microdomains is evident (arrows). This
ranslated into a more uniform coverage of the stent surface (D). Endo-
helial outgrowth cells are labeled with SPM (green). (E and F) Trans-
ission electronic microscopy confirms uniform cytoplasmic capture of
PM microspheres (E). Scanning electron microscopy shows early accu-
ulation of rounded cells to the metal surface (F). (G and H) Represen-
ative en face fluorescent microscopy images (200 magnification) from
xplanted coronary arteries. Local delivery of CM-DiI (red)–labeled EOCs
o a non-magnetized stent containing arterial segment results in retention
f cells in small numbers (G). Local delivery is greatly enhanced in the
egment that received a nickel-coated, magnetized stent before EOC
elivery. Note presence of CM-diI–labeled cells along a stent strut (H).method of localizing cells within the vasculature would
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November 7, 2006:1839–45 Magnetically Targeted Cell Localizationlso enhance the ability to develop novel local or regional
ell-based therapies.
Several methods of coating stents with endothelial cells
ave been described, but none appear to have provided the
fficacy, safety, and ease of use required for clinical applica-
ion. Chemical and biologic modifications of stent surfaces,
ncluding the addition of adhesion molecules and antibodies,
ave been proposed (10,25–30). A common drawback to these
pproaches is that a peripherally or locally delivered cell must
rst come into contact with its putative binding site by random
nteraction and then overcome the shear forces generated by
lood flow until additional cellular attachments are formed.
arly reports with a CD34 cell capturing stent show
romise, with a restenosis rate of 13.3% at 6 months (28),
ut long-term results are not available. Because the exact
ature and cell markers of the putative endothelial progen-
igure 4. Arteries retain more EOCs in the presence of magnetized stents.
A) Cell retention in vivo was significantly higher on magnetized (solid
ars) versus non-magnetized control stents (open bars) for both femoral
nd coronary position. *p  0.05 for magnetized versus non-magnetized
tent. (B) Overlapping, composite, low-power microscopic images of the
uminal surface of a porcine coronary artery showing distribution of labeled
ells along stent tines and the adjacent denuded endothelium. Abbrevia-
ions as in Figure 1.tor cell remain elusive, most reports have focused on aoating devices with receptors for known/presumed mark-
rs. Although endothelial progenitor cells likely express such
arkers, their exclusivity is unknown. Recruiting circulating
rogenitor cells based on such an approach raises questions
bout the possibility of unpredicted/unwanted effects owing
o the capture of inappropriate cells. A recent report showed
hat coverage of arterio-venous grafts with a CD34 receptor
esults in near-complete endothelialization; however, mor-
hometric analysis of grafts 4 weeks after implantation
howed significantly higher restenosis rates in the CD34-
oated grafts when compared with control subjects (30).
ur approach consists of using endothelial outgrowth cells,
hich during culture have achieved a more defined and
omogenous endothelial cell phenotype (16,17).
Local cell delivery during prolonged occlusion of blood
ow has been shown to result in cell attachment to the
essel wall but is impractical for clinical use (18). The
oncept of localizing iron-loaded cells by external magnetic
elds was first described by Consigny et al. (31). In a rabbit
odel of femoral artery injury, increased adhesion of
uperparamagnetic-loaded endothelial cells was achieved by
pplying a magnet external to the injured area. However,
xtended dwell times were needed, and the cell adhesion
as primarily on the vessel wall closest to the magnet. We
ave previously used superparamagnetic labeling to instantly
oat the inner surface of magnetized Dacron grafts (22) with
ndothelial cells. These grafts were used to replace sections
f porcine carotid arteries and demonstrated excellent cell
etention after being subjected to high flow rates in vivo. A
imilar “pre-coating” of stents, although feasible, would
esult in significant cell loss during balloon inflation for
tent deployment.
Magnetic forces may provide an elegant solution for cell
apture. Cells could potentially be guided to a desired site
nd retained in place until they are able to form enduring
iologic attachments. Literature describing the development
f superparamagnetic tags used for magnetic resonance
maging (MRI)-based cell tracking supports the concept
hat endocytosed superparamagnetic particles are effectively
nert in the concentrations commonly used (32,33). We
ere able to successfully identify a concentration that
ermitted magnetic capture while having little impact on
he viability, proliferation, or cytokine secretion profile of
he cultured EOCs. These labeled cells resisted dislodge-
ent when subjected to flow chamber rates similar to
hysiologic conditions. Local cell delivery during brief
essation of flow was sufficient to allow cell capture in the
orcine model. A 5-min cessation of flow would be unde-
irable for human coronary applications. This time could be
educed by increasing the magnetic charge on the stent or by
oncentrating cells further by providing simultaneous prox-
mal and distal occlusion. A double-balloon system with a
erfusion port to permit distal blood flow may provide
dditional safety.
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Magnetically Targeted Cell Localization November 7, 2006:1839–45The weak magnetic field generated by magnetized stents
s likely to create localized imaging artifacts if an individual
equires an MRI, but is unlikely to result in contraindication
f future imaging. Iron oxide particles can be detected by
RI, but the limited quantity of particles used in our
ethod, along with potential stent artifacts, make it unlikely
hat these could be imaged in vivo. Transiently magnetiz-
ble surfaces, as well as biodegradable magnetic compo-
ents, can be developed to completely eliminate magnetic
harges after the cells have formed stable biochemical
onds.
The bulk magnetization of stents is impractical for
niform cell capture because the magnetic poles localize at
he ends of the device and at bends in the struts, resulting in
neven coverage. The nickel plating on our stents resulted
n microscopic surface irregularities, thereby generating
ultiple small magnetic domains, as shown by the ferrofluid
apping. This enabled an even distribution of delivered
ells. This magnetic interaction was sufficient to resist the
hear forces of blood flow and allowed the cells to form
table biochemical bonds as shown by the substantial in vivo
ell retention at 24 h. Not only did the cells line up along
he stent struts, but they were also found to have spread to
enuded areas between the stent struts, thereby indicating
rocedural efficacy extending beyond simple retention on
he stent alone. Control non-magnetized stents showed
nly a few cells randomly distributed on the vessel wall.
Nickel can be allergenic in certain individuals and was
sed for our short-term studies to demonstrate proof of
oncept. Fully biocompatible stents are being developed for
ong-term studies. In a manner analogous to drug-eluting
tents, magnetic particles may be dispersed in a biocompat-
ble polymer, thereby preventing direct contact with the
lood. The long-term effects of iron-containing EOCs and
hether they facilitate endothelialization are unknown.
hese labeled EOCs, or iron particles released by cell
urnover, could paradoxically lead to accelerated neointima
ormation by triggering local inflammation. The SPM
articles contain polystyrene and are not biodegradable.
uman studies will likely require particles similar to the
linically approved ferumoxide.
The procedure as described was carried out with cultured
ells and cannot, in the present form, be used for individuals
equiring emergent procedures. However, it would also be
ossible to place a magnetizable device during an acute
rocedure, followed by the delivery of labeled cells at a later
ime. A staged delivery of cells would necessitate a second
nvasive procedure. Future studies would also need to
ddress the safety of re-exposure to iron oxide particles in
he event that additional interventions are required. Future
efinements of our strategy include the ex vivo concentration
f progenitor cells followed by immediate labeling and
edelivery to reduce the time frame to 1 day. Develop-
ents in progenitor cell biology may lead to identifica-
ion of alternative cell populations that may be isolated
apidly, yet retain the safety of EOC delivery. Geneticallyodified cells, a combination of cells, or serial delivery of
ifferent cells designed to treat specific conditions can also
e envisaged. Recent experiments in models of vascular
njury with overexpression of eNOS, tissue plasminogen
ctivator, and factor VIII appear promising for localized
herapy (20,34,35). The clinical implications of our ap-
roach extend beyond the re-endothelialization of implant-
ble cardiovascular devices. The ability to localize cells
ithin the vasculature opens the possibility that local
ealing could be accelerated and ischemic downstream
issue treated by overexpression of various factors in modi-
ed endothelial cells.
eprint requests and correspondence: Dr. Gurpreet S. Sandhu,
ivision of Cardiovascular Diseases, Mayo Clinic College of
edicine, 200 First Street SW, Rochester, Minnesota 55905.
-mail: sandhu.gurpreet@mayo.edu.
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